Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights
Provided By GlobeNewswire
Last update: Nov 12, 2024
NEWTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today reported financial results for the third quarter of 2024 and provided a business update.
Read more at globenewswire.com
